Silexion Therapeutics Corp Stock Price, News & Analysis

Silexion Therapeutics (NASDAQ: SLXN) has announced breakthrough preclinical data for its RNA interference therapy SIL204, demonstrating exceptional cancer cell growth inhibition rates. The study showed up to 97% inhibition in pancreatic cancer cells and 90% in colorectal cancer cells, including first-time evidence against the KRAS Q61H mutation.

Key findings revealed dose-dependent inhibition of up to 94% in pancreatic cancer cells with KRAS G12D mutations, 97% inhibition in pancreatic cancer cells with KRAS Q61H mutations, and nearly 90% inhibition in colorectal cancer cells with KRAS G12D mutations. The company is preparing for a Phase 2/3 clinical trial in Q2 2026 to investigate SIL204 for KRAS-driven solid tumor cancers.

Silexion Therapeutics (NASDAQ: SLXN), a clinical-stage biotech company developing RNAi therapies for KRAS-driven cancers, has announced a 1-for-15 reverse share split effective after market close on July 28, 2025. Trading on a split-adjusted basis will begin on July 29, 2025.

The reverse split will automatically combine every fifteen ordinary shares into one share, with the par value increasing from $0.0009 to $0.0135 per share. The move aims to maintain Nasdaq listing compliance and follows recent preclinical breakthroughs with SIL-204. Shareholders holding shares in book-entry form or through brokers will have their shares automatically adjusted.

Silexion Therapeutics (NASDAQ: SLXN) has announced positive preclinical results for its SIL204 drug candidate in human lung cancer cell lines. The study demonstrated significant dose-dependent inhibition in lung cancer cells with KRAS G12D mutations, validating the company's lipid-conjugated delivery system.

The company is preparing for a Phase 2/3 clinical trial in Q2 2026 to investigate SIL204 for KRAS-driven solid tumor cancers, utilizing both intratumoral and systemic delivery approaches. Silexion is also conducting additional studies on a previously untested KRAS mutation to potentially establish SIL204 as a pan-KRAS treatment.

The target market is substantial, with KRAS mutations present in 90% of pancreatic cancers, 45% of colorectal cancers, and 30% of lung cancers, representing a combined global treatment market exceeding $30 billion annually.

Silexion Therapeutics (NASDAQ: SLXN) has announced breakthrough preclinical results for its RNAi therapeutic candidate SIL204, showing significant efficacy against pancreatic, colorectal, and lung (NSCLC) cancer cell lines. The drug demonstrated powerful anti-tumor activity in cells with KRAS G12D mutations, achieving an impressive ~90% inhibition rate in GP2D colorectal cancer cells. SIL204's lipid-conjugated delivery system enabled potent activity at nanomolar concentrations across multiple cancer types. The therapy targets KRAS mutations, which occur in approximately 90% of pancreatic cancers, 45% of colorectal cancers, and 35% of non-squamous non-small-cell lung cancers. These indications represent a combined global treatment market exceeding $30 billion annually.

Silexion Therapeutics (NASDAQ: SLXN) has completed a crucial preclinical study evaluating its RNAi therapeutic candidate SIL204 across multiple cancer types. The study assessed SIL204's potential in treating colorectal cancer (GP2D), lung cancer (A427), and pancreatic cancer (Panc-1) cell lines with KRAS mutations.

The company plans to announce comprehensive results in the coming days. This expansion beyond pancreatic cancer targets a significant market opportunity, as KRAS mutations occur in approximately 90% of pancreatic cancers, 45% of colorectal cancers, and 35% of non-small-cell lung cancers. The combined treatment market for these indications exceeds $30 billion annually.

Silexion Therapeutics (NASDAQ: SLXN) reported Q1 2025 financial results and business updates, highlighting significant progress in their RNAi therapy development for KRAS-driven cancers. Their lead candidate SIL204 demonstrated remarkable efficacy in preclinical studies, showing ~70-80% reduction in tumor cells and decreased metastatic spread in orthotopic models. The company strengthened its financial position by raising over $9 million in gross funds during Q1. Cash position improved to $6.2 million as of March 31, 2025, up from $1.2 million at end-2024. Q1 operating expenses were $1.7 million, with net loss at $1.7 million. The company announced a strategic collaboration with Catalent for SIL204's formulation development and unveiled plans for clinical trials in H1 2026.

Silexion Therapeutics (NASDAQ: SLXN) has announced a strategic collaboration with Catalent for the formulation development and clinical manufacturing of SIL204, their next-generation siRNA candidate. The partnership will utilize Catalent's Limoges facility in France to optimize both systemic and intratumoral delivery formulations of SIL204.

The collaboration follows Silexion's recent preclinical breakthrough showing SIL204's efficacy in reducing primary tumor growth and metastatic spread in pancreatic cancer models. SIL204 targets multiple KRAS mutations (G12D, G12V, G12R, Q61H, and G13D) important in pancreatic, colorectal, and lung cancers.

The company aims to initiate human clinical trials in H1 2026, with plans for regulatory submissions to the Israel Ministry of Health in H2 2025 and to the European Union in H1 2026. Throughout 2025, Silexion will conduct additional toxicology and pharmacodynamic studies as part of their comprehensive development strategy.

Silexion Therapeutics (NASDAQ: SLXN) has announced an expanded development plan for SIL204, its next-generation siRNA candidate targeting KRAS-driven pancreatic cancer. The new strategy combines both intratumoral and systemic administration approaches to target primary tumors and metastases.

The expansion follows promising preclinical data showing significant tumor growth inhibition in orthotopic models through systemic administration. Recent studies demonstrated SIL204's ability to reduce metastases to secondary organs, with pharmacokinetic data showing sustained drug levels for approximately two months after a single subcutaneous dose.

The development roadmap includes:

• Additional toxicology and pharmacodynamic studies throughout 2025
• Planned regulatory submissions to Israel Ministry of Health in H2 2025
• European Union submission targeted for H1 2026
• Human trials initiation planned for H1 2026

Silexion Therapeutics has completed an expanded development plan for SIL204, its next-generation siRNA candidate targeting KRAS-driven cancers. The plan will be presented at the NeauxCancer 2025 Conference in New Orleans from March 27th-29th, 2025.

The strategic plan, building on recent promising preclinical data, aims to maximize SIL-204's potential across multiple delivery approaches. The company's presentation is scheduled for March 28th at 1:00pm during the conference's Innovation track, where they will present their strategic vision alongside recently reported preclinical findings.

The clinical-stage biotechnology company, specializing in RNA interference (RNAi) therapies, will focus particularly on pancreatic cancer in their comprehensive approach to targeting KRAS-driven cancers.